Back to Search
Start Over
The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.
- Source :
-
Pulmonary medicine [Pulm Med] 2021 Mar 17; Vol. 2021, pp. 8881895. Date of Electronic Publication: 2021 Mar 17 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Both asthma and chronic obstructive pulmonary disease (COPD) are inflammatory chronic respiratory conditions with high rates of morbidity and mortality worldwide. The objectives of this review are to briefly describe the pathophysiology and epidemiology of asthma and COPD, discuss guideline recommendations for uncontrolled disease, and review a new generic option for the treatment of asthma and COPD. Although mild forms of these diseases may be controlled with as-needed pharmacotherapy, uncontrolled or persistent asthma and moderate or severe COPD uncontrolled by bronchodilators with elevated eosinophilia or frequent exacerbations may require intervention with combination therapy with inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs), according to international guidelines. Fixed-dose combinations of ICS/LABA are commonly prescribed for both conditions, with fluticasone propionate (FP) and salmeterol forming a cornerstone of many treatment plans. An oral inhalation powder containing the combination of FP and salmeterol has been available as Advair Diskus® in the United States for almost 20 years, and the first and only substitutable generic version of this product has recently been approved for use: Wixela™ Inhub™. Bioequivalence of Wixela Inhub and Advair Diskus has been established. Furthermore, the Inhub inhaler was shown to be robust and easy to use, suggesting that Wixela Inhub may provide an alternative option to Advair Diskus for patients with asthma or COPD requiring intervention with an ICS/LABA.<br />Competing Interests: In accordance with the disclosure policy and our ethical obligations as researchers, we disclose the following interests fully and have in place an approved plan for managing any potential conflicts arising from these interests: Donald P. Tashkin has been a paid consultant for Innoviva and an advisory board member and paid speaker for AstraZeneca, Boehringer-Ingelheim, Sunovion, and Mylan Inc. Jill A. Ohar has received an investigator-initiated grant from Sunovion and has been a paid consultant for Boehringer-Ingelheim, GlaxoSmithKline, Mylan Inc., Theravance, and Sunovion. Arkady Koltun is a Mylan Inc. employee, stock owner, and shareholder. Richard Allan is a Mylan Pharma UK employee and stock owner. Jonathan K. Ward is a Mylan Pharma UK employee and stock owner.<br /> (Copyright © 2021 Donald P. Tashkin et al.)
- Subjects :
- Administration, Inhalation
Drugs, Generic pharmacokinetics
Drugs, Generic therapeutic use
Health Services Needs and Demand statistics & numerical data
Humans
Nebulizers and Vaporizers
Powders pharmacokinetics
Powders therapeutic use
Practice Guidelines as Topic
Standard of Care
Therapeutic Equivalency
Asthma drug therapy
Asthma epidemiology
Asthma physiopathology
Bronchodilator Agents pharmacokinetics
Bronchodilator Agents therapeutic use
Fluticasone-Salmeterol Drug Combination pharmacokinetics
Fluticasone-Salmeterol Drug Combination therapeutic use
Glucocorticoids pharmacokinetics
Glucocorticoids therapeutic use
Pulmonary Disease, Chronic Obstructive drug therapy
Pulmonary Disease, Chronic Obstructive epidemiology
Pulmonary Disease, Chronic Obstructive physiopathology
Subjects
Details
- Language :
- English
- ISSN :
- 2090-1844
- Volume :
- 2021
- Database :
- MEDLINE
- Journal :
- Pulmonary medicine
- Publication Type :
- Academic Journal
- Accession number :
- 33815843
- Full Text :
- https://doi.org/10.1155/2021/8881895